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Background: The obese Zücker diabetic fatty male rat (ZDF:Gmi™-fa) is an animal model of type II diabetes
associated with obesity and related metabolic disturbances like dyslipidaemia and diabetic nephropathy. In
addition, diabetic dyslipidaemia has been linked to vascular and glomerular damage too. Dietary fat restriction is
a current strategy to tackle obesity and, telmisartan, as a renoprotective agent, may mediate cholesterol efflux by
activating PPARγ. To test the hypothesis that both therapeutical alternatives may influence dyslipidaemia and
nephropathy in the ZDF rat, we studied their effect on development of diabetes.
Methods: Male Zücker Diabetic Fatty (ZDF) rats received a low-calorie diet, vehicle or telmisartan for 9 weeks.
Blood samples were obtained for analyses of lipids and lipoproteins, LDL-oxidisability, HDL structural and functional
properties. Urinalysis was carried out to estimate albumin loss. At the end of the experimental period, rats were
sacrificed, liver extracted and APOA1 mRNA quantified.
Results: Results indicated that low-calorie diet and telmisartan can slower the onset of overt hyperglycaemia
and renal damage assessed as albuminuria. Both interventions decreased the oxidative susceptibility of LDL and
hepatic APOA1 mRNA expression but only dietary restriction lowered hyperlipidaemia.
Conclusion: Either a dietary or pharmacologic interventions with telmisartan have important beneficial effects in
terms of LDL oxidative susceptibility and progression of albuminuria in obesity related type II diabetes.
Keywords: Zücker diabetic fatty rat, Type II diabetes, Dyslipidaemia, Caloric restriction, Telmisartan, Mildly oxidized LDLBackground
Incidence and prevalence of obesity and diabetes have
increased considerably in recent years [1,2]. They both rep-
resent a major public health concern in terms of morbidity
and mortality, due to their association with cardiovascular
disorders, resulting from metabolic disturbances (athero-
genic dyslipidaemia and hyperglycaemia), inflammatory
status and endothelial dysfunction that led to atheroscler-
osis [3,4].
Zücker obese and diabetic rat (ZDF/Gmi-fa) is an
animal model frequently used to study obesity and re-
lated metabolic disturbances like dyslipidaemia and
non-insulin dependent diabetes [5]. They also develop* Correspondence: eduardo.lezcano@gmail.com
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stated.diabetic nephropathy with proteinuria and focal glo-
merulosclerosis that end in renal insufficiency [6].
Low serum levels of HDL cholesterol (HDL-c) are
consistently associated with increased risk for all forms
of atherosclerotic disease and its clinical sequelae, inclu-
ding myocardial infarction, stroke, and sudden death.
HDL particles have been studied in vitro, in animal
models, and in humans. The classical function of HDL is
reverse cholesterol transport from macrophages. How-
ever, HDL particles inhibit many inflammatory activities,
inhibit oxidation of lipoproteins and cell membranes,
and help to maintain endothelial function and integrity
too. They also exert anticoagulant effects by inhibiting
coagulation proteins and platelet aggregation. Further-
more, HDL has been found to improve beta cell survival
and insulin secretion in diabetic patients and to reduce
insulin resistance in muscle and adipose tissues [7]. HDLl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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size. APOA1 plays a key role for cholesterol efflux, but
there are other components of the HDL particle such as
apolipoproteins, antioxidant enzymes or lipids besides
cholesterol that confer HDL its beneficial properties [8].
In patients with certain diseases (diabetes, cardiovascular
diseases, etc.), the different proteins and lipids commonly
found in HDL particles may undergo modifications such
as amino acid oxidation, protein loss, proteolytic degrad-
ation, protein glycation, and many other harmful modifi-
cations that interfere with HDL function [9,10].
There is a beneficial effect of dietary restriction and
weight reduction on the hyperglycaemia of patients with
obesity-associated non-insulin-dependent diabetes mellitus
(NIDDM). A low-energy diet recommended for the treat-
ment of obesity should be low fat (25-35% total energy),
high carbohydrate, high protein, and high fiber [11,12].
Caloric restriction in obese pre-diabetic rats prevents
hyperglycaemia, beta-cell depletion, loss of beta-cell GLUT
2 and glucose incompetence [21].
Nuclear PPARγ receptor is a transcription factor regu-
lating many genes related to adipogenesis, lipid metabol-
ism and insulin sensitivity [13]. Mainly known for its
angiotensin II receptor blocker (ARB) and anti-hyperten-
sive action, telmisartan is also a partial PPARγ agonist
[14,15]. The purpose of this study was to examine the
effects of PPARγ modulation using telmisartan, or caloric
restriction on plasma lipoprotein profile, plasma APOA1
and its hepatic expression, in an early stage of vascular




Male Zücker obese (fa/fa) and Male Zücker Diabetic
Fatty (ZDF) rats, weighing 250–300 g (purchased at 8
weeks of age from Charles River, Barcelona, Spain), were
used for experiments. Rats, housed in sterile filter-top
cages, were acclimatized in a room maintained at 20°C
with a 12-h light–dark cycle for 10 days, allowed ad
libitum access to water and standard chow diet (Purina
LabDiet® 5008 diet; Purina S.A. Spain). ZDF rats were
randomly assigned to three groups of eight animals each:
a low-calorie diet (ZDFD), vehicle (ZDFV) or treatment
(1.5 mg/kg telmisartan, ZDFT). In addition, male Zücker
rats (n = 5) were used as control to observe the early
effects of obesity related diabetes. Animals in the hypo-
caloric diet were fed with a 30% low-calorie diet (Purina
LabDiet® 5008 diet). Telmisartan (Boehringer Ingelheim
Pharma KG, Ingelheim, Germany) was dissolved in 1 N
NaOH and then in water, and the solution adjusted at
pH 7.4. Telmisartan (1.5 mg/kg/day) or the vehicle were
orally administered once daily in the morning from
weeks 10 to 19. The animals were handled and killedalways observing criteria from the European Union for
care and use of laboratory animals in research, and the
protocol was approved by the Ethics Committee for
Animal Research of the University of Zaragoza.
Blood samples were obtained from tail vein at weeks
10 (after 2-week quarantine), 14, and 19, after an 18 h-
fasting period. Blood samples were collected in heparin
coated capillary tubes and centrifuged at 2000 g for 5 min.
At the moment of sacrifice (18 h after the feeding), rats
were anesthetized with 1 ml of 8% Avertine (Aldrich
Chemical Co., Madrid, Spain) in 0.1 M phosphate, pH 7.2,
and blood drawn from hearts. Blood was collected in
tubes containing 1 g/l sodium EDTA. Liver was removed
and quickly frozen in liquid N2 until total RNA was
extracted.
Urinalysis
Twenty-four-hour urine samples were collected from all
animals using metabolic cages while providing food and
water. After urine volume was measured, the samples
were centrifuged at 1500 rpm for 5 minutes at room
temperature in order to separate the supernatant from
the residue. Urinary albumin was measured with an
immunoenzymatic assay method Rat Albumin EIA kit
(SPI bio, France).
Blood chemistry
In all animals, plasma creatinine was assayed using
QuantiChrom™ Creatinine Assay Kit (DICT-500) (Bio-
Assay Hayward, CA, USA), blood urea nitrogen (BUN)
and glucose were determined using Vetscan (Abaxis, Inc.,
USA), analyzer.
Lipid and lipoprotein analyses
Total plasma cholesterol, triglyceride (corrected for free
glycerol) and non-esterified fatty acids (NEFA) concen-
trations were quantified enzymatically in a microtiter
assay using commercial kits (Thermo scientific, Madrid,
Spain) and (Wako, Madrid, Spain). Cardiolipid (Sigma)
was used as quality control. Plasma lipoprotein profile
was determined in 100 μl of plasma samples by fast protein
liquid chromatography (FPLC) gel filtration using a Super-
ose 6B column (Amersham Pharmacia, Barcelona, Spain),
and the total cholesterol in each fraction was measured
using a fluorometric method (Amplex Red, Molecular
Probes, USA). Apolipoprotein, APOA1, was quantified by
ELISA using specific polyclonal antibodies (Biodesign,
Saco, ME, USA), as previously described [16].
LDL oxidation susceptibility
LDL oxidisability was assessed using modified proce-
dures of Navab et al. [17] to determine the presence of
reactive oxygen species (ROS) by measuring the con-
version of 2’,7’-dichlorofluorescein diacetate (DCFH-DA)
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FPLC-separated LDL fractions (5 μg of cholesterol) were
incubated, at 37°C with 2 microg of DCFH-DA, in 25 μl of
0.1% sodium azide and 100 μl of PBS, up to a total volume
of 150 μl. The fluorescence was measured after 3 h of
incubation at 485 nm excitation and 535 nm emission
wavelengths. The ability of HDL to inactivate LDL ROS
was also tested.
RNA isolation
RNA from each liver was isolated using Tri reagent
(Sigma). DNA contaminants were removed by TURBO
DNAse treatment using the DNA removal kit from
AMBION (Austin, TX, USA). RNA was quantified by
absorbance at 260 and 280 nm. The A260/280 ratio did not
vary significantly among groups. The integrity of the 28S
and 18S ribosomal RNAs was verified by 1% agarose gel
electrophoresis of 500 ng of total RNA. Ethidium-bromide
stained gels were exposed to UV light and images were
captured (BioRad, Madrid, SpA-In). Intensity of bands for
each condition was calculated using Quantity One® soft-
ware version 4.5.0 (BioRad). The 28S/18S ratio did not
differ among groups. RNA integrity number (RIN) from
samples was obtained by RNA nano kit using an Agilent
2100 Bioanalyzer. RIN values were not significantly differ-
ent among tested groups.
Quantification of mRNA
The mRNA expression was analysed by reverse tran-
scriptase and quantitative real-time polymerase chain
reaction (RT-qPCR). Equal amounts of DNA-free RNA
from each sample of each animal were used. First-strand
cDNA synthesis and the PCRs were performed using the
SuperScript II Platinum Two-Step RT-qPCR Kit with
SYBR Green (Invitrogen, Madrid, Spain), according to
the manufacturer’s instructions and as previously des-
cribed [18]. Primers were designed by Primer Express®
(Applied Biosystems, Foster City, CA) and checked by
BLAST analysis (NCBI) to verify specificity and selective
amplification of the target gene as well as to get ampli-
fication of the cDNA and not of genomic DNA. The
sequences have been published [19]. Real time PCRsTable 1 Follow-up of body weights and glucose concentration
Body weight (g)
Animal 10 19 Weight increase
Z 330 ± 23 517 ± 34 187 ± 35
ZDFV 356 ± 22 433 ± 35* 76 ± 22*
ZDFT 360 ± 14 480 ± 68 119 ± 62
ZDFD 337 ± 13 495 ± 15¶ 158 ± 14
Differences between the experimental time-points (weeks 10 and 19) in the non-di
differences *p < 0.05 vs Zücker, ¶p < 0.05 vs ZDFV. The greater weight increase was
caloric restriction (ZDFD). Conversely, in the vehicle group (ZDFV), we saw a trend t
over time.were performed in an ABI PRISM 7700 Sequence Detec-
tor (Applied Biosystems) following the standard pro-
cedure. The specificity of the PCR was confirmed by
observing a single dissociation curve and no template
controls were carried out to reject unintended amplifica-
tion. Each sample was analyzed in duplicate obtaining
an average Cq for sample. The relative amount of all
mRNAs was calculated using the comparative 2-ΔΔCq
method and normalized to the reference Rn18s mRNA
expression [17].
Statistical analysis
The results are expressed as means ± SD. Comparisons
were made using one-way ANOVA and the Tukey-
Kramer multiple comparison test (post hoc) when the
distribution of the variables was normal. When the
variables did not show such a distribution (according to
the Shapiro-Wilk test), or failed to show homology of
variance, comparisons were calculated by the Mann–
Whitney U-test. Correlations between variables were
sought using the Pearson or Spearman correlation coef-
ficients. SPSS version 15.0 (SPSS Inc, Chicago, IL) were
used for calculations. Significance was set at P < 0.05.
Results
Effects of telmisartan or caloric restriction on body weight,
plasma glucose and albuminuria
As shown in Table 1, mean body weight increased pro-
gressively during study period in all animals with a trend
to a slower weight gain in the obese and diabetic Zücker
rats when no treatment was administered (vehicle). At
19 weeks of age, mean body weight was only slightly
greater in that vehicle group. The greater weight in-
crease is statistically significant in the non-diabetic and
the diabetic groups subjected to caloric restriction versus
the vehicle group. Conversely we clearly see a marked
increase in hyperglycaemia in that vehicle group over
time, with statistically significant differences versus the
other obese and diabetic animals that were subjected to
any of the interventions.
Urinary excretion of albumin gradually increased in all
groups as shown in Table 2. At 19 weeks, non-diabetics
Glucose (mg/dL)
10 19 Glucose increase
150 ± 16 188 ± 78 38 ± 72
201 ± 96 593 ± 63* 416 ± 103*
223 ± 130 478 ± 115*¶ 218 ± 121*¶
146 ± 23 360 ± 119*¶ 213 ± 130*¶
abetic and diabetic obese rats. Data are shown as mean ± SD. Significant
seen in the non-diabetic rats (Z) and the fatty-diabetic animals subjected to
o a slower weight gain but the most marked increase in hyperglycaemia
Table 2 Follow-up of plasma creatinine concentrations and urinary albumin excretions
Animal Serum creatinine (mg/dL) Albuminuria (mg/day)
10 19 Creatinine increase 10 19 Albuminuria increase
Z 0.25 ± 0.05 0.34 ± 0.11 0.05 ± 0.05 4.42 ± 0.86 37.20 ± 17.20 32.78 ± 17.52
ZDFV 0.45 ± 0.38 0.32 ± 0.10 −0.13 ± 0.33 57.31 ± 48.8 323.63 ± 134.3 260.37 ± 124.8*
ZDFT 0.40 ± 0.31 0.28 ± 0.12 −0.16 ± 0.21 24.73 ± 9.6 97.80 ±57.4¶ 73.07 ± 54.2¶
ZDFD 0.20 ± 0 0.23 ± 0.05 0.03 ± 0.05 19.51 ± 7.81 130.32 ± 66.5*¶ 107.62 ± 64.5*¶
Differences between the experimental time-points (weeks 10 and 19) in the non-diabetic and diabetic obese rats. Data are shown as mean ± SD. Significant
differences *p < 0.05 vs Zücker, ¶p < 0.05 vs ZDFV. The urinary excretion of albumin in the vehicle group at the completion of the study period was significantly
greater than in the other groups, either in the non-diabetic (Z) or in the fatty-diabetic animals with low-calorie diet (ZDFD) and telmisartan (ZDFT). Renal function
and plasma creatinine values did not experience any significant change.
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ary excretion, ranging from traces to microalbuminuria,
whereas the urinary excretion of albumin in the vehicle
group at the completion of the experiment was 10 times
higher and only 3 to 4 times in the other two groups of
diabetic rats (telmisartan and calorie-restricted diet).
The increase in urinary albumin excretion was signifi-
cantly higher in the vehicle group versus telmisartan and
diet restricted groups. No statistically significant differ-
ence between caloric-restricted and telmisartan-treated
animals was observed despite a trend towards a slower
increase in the urinary albumin excretion in the drug
group. Renal function and plasma creatinine values did
not experience any significant change.
Effects of telmisartan or caloric restriction on plasma
lipids and lipoprotein
NEFA, triglycerides, total cholesterol and HDL-cholesterol
values are summarized in Table 3. No statistically signifi-
cant differences were found in circulating NEFA, whereas
a marked and similar increase in plasma triglycerides was
shown in the groups of obese and diabetic rats that there
were not on a restricted diet regardless of they received
vehicle or telmisartan treatment. Values in the non-
diabetic and the diabetic with caloric restriction groups
were only slightly different (lower in the first one), and
both significantly different from drug-or-vehicle-treated
animals (Figure 1).
At the end of experimental intervention, hyperlipid-
aemia in all groups was mainly due to elevated triglycer-
ides with modest increases in total cholesterol, particularlyTable 3 Final values of plasma lipid, APOA1 and hepatic Apoa
Animal NEFA (mg/dL) Cholesterol (mmol/L) HDL-c mmol/L Tr
Z 39.1 ± 8.2 7.4 ± 0.6 5.4 ± 0.4 36
ZDFV 42.4 ± 20.0 7.2 ± 2.7 5.2 ± 1.9 10
ZDFT 37.4 ± 16.7 7.1 ± 3.2 5.6 ± 2.5 10
ZDFD 44.2 ± 6.1 3.1 ± 0.6*¶ 2.4 ± 0.5*¶ 51
Differences between non-diabetic and diabetic obese rats at the end of experimental
*p < 0.05 vs Zücker ¶p < 0.05 vs ZDFV. Hyperlipidaemia in all groups was mainly due to
cholesterol levels, with the exception of the low-calorie diet group (ZDFD) in which ch
APOA1 plasma concentration and hepatic mRNA expression than fatty-diabetic rats thHDL cholesterol levels, with the exception of the low-
calorie diet group in which total cholesterol and its HDL
fraction were significantly less than a half than the others.
Moderate correlation between serum triglyceride concen-
tration and albumin urinary excretion at week 19 was also
found (R = 0.530, p < 0.05).
Effects of telmisartan or caloric restriction on plasma and
hepatic expression of apolipoprotein A1
Plasma APOA1 concentration and its mRNA hepatic
expression are shown in Table 3. Plasma levels in the
non-diabetic rats were significantly lower than the others
regardless of cholesterol and HDL-cholesterol concen-
tration. In contrast, the obese and diabetic rats showed a
trend towards higher plasma concentration. Either in the
telmisartan or in the low-calorie groups plasma APOA1
levels were lower than in the vehicle group (diet vs
vehicle, p = 0.05). APOA1 hepatic mRNA expression
showed statistically significant differences between the
obese and diabetic animals that were on restricted
diet compared to the vehicle ones, in which values
were higher (Figure 2).
Effects of telmisartan or caloric restriction on lipoprotein
oxidation
LDL and LDL +HDL from each group were incubated
and oxidation was tested with the DCF method [17]. Re-
sults are summarized in Table 4. ROS content in LDL
was markedly lower in the diet restricted group, sug-
gesting less oxidation of this lipoprotein, whereas higher
signals were obtained from de non-diabetic and the1 mRNA expression
iglycerides (mg/dL) Plasma APOA1 (AU/L) Hepatic Apoa1 (RAU)
5 ± 202 0.64 ± 0.03 ND
16 ± 654* 0.90 ± 0.1* 1.0 ± 0.4
86 ± 388* 0.78 ± 0.1 0.75 ± 0.2
6 ± 240¶ 0.80 ± 0.06* 0.7 ± 0.3¶
interventions. Data are shown as mean ± SD. Statistically significant differences
elevated triglycerides with modest increases in total cholesterol, particularly HDL
olesterol was significantly less than the others. Fatty-diabetic rats showed higher
































Figure 1 Final values of plasma lipids concentration. NEFA, Triglycerides, total Cholesterol and HDL-cholesterol. Differences between
non-diabetic and diabetic obese rats at the end of experimental interventions. Data are shown as mean ± SD. Statistically significant differences
*p < 0.05 vs Zücker ¶p < 0.05 vs ZDFV. Hyperlipidaemia in all diabetic groups (ZDF) was mainly due to elevated triglycerides with modest increases
in total cholesterol, particularly HDL cholesterol levels, with the exception of the low-calorie diet group (ZDFD) in which cholesterol was significantly
less than the others.
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incubating LDL of each group with its own HDL, very
little fluorescent signal change was found for all groups
with the exception of the obese and diabetic rats receiv-
ing vehicle, where the signal decreased substantially.
Association among parameters
At the end of the study in a bivariate analyses, we found
significant correlations between the increase in the
urinary albumin excretion and the glycaemia (R = 0.74,
p < 0.05). APOA1 also showed a positive correlation
with the urinary albumin excretion (R = 0.66, p < 0.05),
while body weight increase was inversely correlated


























Figure 2 Final values of plasma APOA1 and APOA1 hepatic mRNA. Di
experimental interventions. Data are shown as mean ± SD. Statistically sign
rats showed higher APOA1 plasma concentration and hepatic mRNA expre
telmisartan treatment (ZDFT).LDL oxidisability using DCF test with and without HDL,
its average fluorescent signal of the difference, and media
of urinary albumin excretion are depicted in Figure 3.
Good correlations were also found between DCF signal
difference between LDL and LDL +HDL and the increase
in the urinary albumin excretion (R = 0.63) and inversely
body weight increase (R = − 0.64).
Discussion
The ZDF rat is an inbred rat model obtained through
selective breeding (fa mutation) that results in shortened
leptin receptor which does not effectively interact with
leptin and is phenotypically expressed as obesity with

























fferences between non-diabetic and diabetic obese rats at the end of
ificant differences *p < 0.05 vs Zücker ¶p < 0.05 vs ZDFV. Fatty-diabetic
ssion than fatty-diabetic rats that were on low-calorie diet (ZDFD) or




Z LDL 63 10
LD + HDL 61 9
ZDFV LDL 63 10
LD + HDL 45 7
ZDFT LDL 46 8
LD + HDL 43 7
ZDFD LDL 29 4
LD + HDL 31 4
Data are expressed as arbitrary fluorescence units and are mean ± SD of the
groups. ROS content in LDL was markedly lower in the diet restricted group.
Very little fluorescent signal change was found for all groups with the
exception of the obese and diabetic rats receiving vehicle when incubating
with HDL.
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develop obesity, hyperlipidemia, fasting hyperglycaemia
and non-insulin dependent diabetes (NIDDM).
We observed a trend towards high glucose plasma
concentration in all groups since the first time point. At
week 10, hyperglycaemia was modestly higher in the
vehicle group in which diabetes seems to develop earlier
whereas low-calorie diet could delay the onset of a
diabetic state similar to obese non-diabetic Zücker rats.
Nine weeks later, the plasma glucose level in the vehicle
group was up to three times higher than in the non-
diabetic one, and almost two times than in the diet
restricted group. This rapid increase in glucose level in
the vehicle group due to an overt diabetic state was
partially controlled by both interventions with telmisartan











Figure 3 Ability of HDL to inactivate ROS present in LDL and albumin
increase in urinary albumin excretion between 10 and 19 weeks, and is exp
oxidisability as the difference between the average fluorescent signals on t
group; the greatest DCF difference is seen in the vehicle group, with the laOn the contrary, greater weight increase rate was
found in the non-diabetic animals and minor in the
diabetic vehicle group, whereas rats subjected to caloric
restriction or telmisartan showed moderate increase
during experiment. In work by Corsetti et al. as hyper-
glycaemia developed with a higher dietary fat-content
weight increased slower [20]. Ohneda et al. also showed
that when ZDF rats are fed with an unrestricted diet
they became hyperglycaemic by 8 weeks of age, whereas
all diet-matched rats remained euglycaemic despite the
fact that at 18 weeks of age their mean body weight
equalled that of obese rats on an unrestricted diet
[21]. As we could see, rats on a moderate caloric re-
striction diet with a well-adjusted nutrient content
showed a normal growth whereas animals on an un-
restricted diet had only a markedly increase in body
fat content but weight increase was hindered by the
severe catabolic state associated with earlier and more
severe diabetes as it was suggested by Corsetti and
colleagues.
Telmisartan can modulate PPARγ by improving insu-
lin sensitivity without fluid retention [14]. Upton et al.
demonstrated that ZDF rats treated with experimental
thiazolidinedione MCC-555 improved metabolic status
and insulin sensitivity, and had a small but significant
increase in body weight gain during experimental period
whereas vehicle-treated animals did not [22]. Despite the
marked hyperphagia in diabetic ZDF rats, they do not
continue to gain weight after 15–20 weeks of age due to
heavy losses of energy as glycosuria and higher catabol-
ism. The body weight gain in diabetic ZDF rats following
telmisartan treatment is probably the result of increase



















uria in the different experimental groups. Red line represents the
ressed as mean ± SD in every group. Blue line represents LDL
he DCF assay between the incubation with or without HDL of each
rgest amount of albuminuria.
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group was significantly higher than groups on caloric re-
stricted diet or telmisartan treatment at week 19, but also
since week 14 (data not shown), as well as the increase in
albuminuria since the starting point at the experimental
period. Albuminuria correlates with endothelial dysfunc-
tion and predicts cardiovascular outcomes by its predis-
position to systemic atherosclerosis [23].
With increasing age, fa/fa-rats spontaneously develop
proteinuria and focal segmental glomerulosclerosis (FSGS),
eventually leading to renal failure [24]. The development
of proteinuria and/or FSGS in fa/fa-rats can be amelio-
rated by treatment with a 3-hydroxy-3-methyl-glutaryl-co-
enzyme A (HMG-CoA) reductase inhibitor [25]. When
studying diabetic ZDF, Coimbra et al. showed that the
animals exhibited pronounced hyperinsulinemia and
hyperlipidaemia at 6 weeks and became diabetic after 14
weeks of age. Significant FSGS nephropathy was first
noted in 18-week-old fa/fa-rats and tubulointerstitial
damage and proteinuria in 40-week-old fa/fa-rats but pro-
gressive glomerular hypertrophy was already detected in
diabetic fa/fa rats after 10. They suggested that early pro-
gressive podocyte damage and macrophage infiltration
was associated with type II diabetes mellitus but also with
hyperlipidaemia [26]. Noda et al. [27] examined the role of
angiotensin II in obese Zücker rats and suggested that
angiotensin II is the main cause of diabetic nephropathy
as is the case in diabetic patients. Increase in proteinuria
and albuminuria are inhibited by ACE-I or ARB in ani-
mals [28]. Therefore, as in the work by Ohmura et al. [29],
it is possible that the renoprotective effect of telmisartan
may be induced at least in part by inhibition of the renal
hypertensive effect of angiotensin II based on the anta-
gonistic activity to the AT1 receptor, but also by its non-
hemodynamic effects in relation to cell proliferation, renal
sclerosis and fibrosis stimulated by angiotensin II [30].
They showed that even at low doses, telmisartan inhibited
the increase in albuminuria and was associated with a
significant decrease in the progression of glomeruloscle-
rosis. Our findings are consistent with their conclusions
regarding those renal changes.
Our results suggest that a low-calorie diet can prevent
urinary loss of albumin and therefore early renal damage
probably by its lipid lowering effect and slowing the
rapid decline in insulin sensitivity. Works by Sparks-
Corsetti et al. showed a significant increase over time in
serum cholesterol concentration in the higher dietary fat
diet relative to the lowest fat-content diet and triglycer-
ides concentration in male ZDF rats. Previously that
group had reported an extensive characterization of the
diabetic dyslipidaemia in obese ZDF rats that was ini-
tially due to triglyceride and free fatty acids but followed
by an additionally rise in serum total cholesterol (LDL
and HDL cholesterol) in the insulinopenic state, by 20weeks of age [20,31]. In this study, telmisartan did not
show the same effect as with restricted diet, probably
due to low dose of treatment and short experimental
period. According to Ohmura et al. telmisartan did only
inhibit the increase in blood cholesterol and triglycerides
with higher doses of telmisartan and longer treatment
periods [26].
We also found moderate correlation between serum
triglyceride concentration and albumin urinary excretion.
As mentioned above, treatment of hyperlipidaemia can
reduce glomerular injury in obese Zücker rats. Work by
Joles et al. [32] showed that analbuminemic rats with
hypertriglyceridemia developed podocyte injury and glo-
merulosclerosis, and that hypertriglyceridemia, protein-
uria, and the increase in desmin staining (podocyte injury)
were largely prevented by ovariectomy.
Regarding APOA1 either in serum or in hepatic tissue,
to our knowledge, this is the first report on plasma
APOA1 concentration and hepatic mRNA expression in
ZDF rats subjected to low-calorie diet or telmisartan.
Current data shows a trend towards higher plasma
APOA1 concentration as well as mRNA hepatic expres-
sion when animals are not treated with telmisartan and
are fed a normal chow. A study by Sparks et al. [31] in
hyperinsulinemic and insulinopenic Zücker diabetic fatty
rats showed increases both APOA1 and APOA4 levels
more than doubled between 10 and 20 weeks in ZDF
rats as hyperglycaemia and hypercholesterolemia devel-
oped. In our experiment conditions, the effect of PPAR
modulation with low dose telmisartan and caloric restric-
tion seems to be independent of serum cholesterol levels
since there were no differences between vehicle and
telmisartan-treated group. This could be explained by the
non-linear relationship between HDL and APOA1 levels
depending on the type of HDL-particle analysed [33]. A
good correlation between serum APOA1 levels and the in-
crease in glycaemia was observed in the present study.
Murao et al. [34] showed that transcriptional activity of
the rat APOA1 promoter in HepG2 cells paralleled the
endogenous mRNA expression, and this activity was de-
pendent on the dose of glucose or insulin: glucose de-
creases and insulin increases APOA1 promoter activity,
respectively. We found that endogenous mRNA expres-
sion paralleled serum apolipoprotein concentration. How-
ever, animals with marked hyperglycaemia and severe
diabetes showed higher serum APOA1 concentration
suggesting a positive regulation in vivo.
Oxidation of LDL is thought to contribute to the
development of atherosclerosis. Using the dichlorofluores-
cein analysis (DCF), the high fluorescent signal generated
by LDL-oxidized-phospholipids in the vehicle group sug-
gests a greater pro-inflammatory and pro-atherosclerosis
state in the obese and diabetic animal group than the
others. On the contrary, LDL from calorie-restricted diet
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strated that normal HDL inhibited the fluorescent signal
generated by oxidized phospholipids in the cell-free assay
using dichlorofluorescein, whereas patient (with definite
coronary atherosclerosis) HDL did not. In our study when
incubating this oxidized LDL from vehicle group with its
own HDL, we saw a decrease in the fluorescent signal,
suggesting intact beneficial properties of HDL in this early
setting when preventing the formation or inactivating
oxidized phospholipids. As mentioned above good corre-
lations were also found between the DCF signal difference
between LDL and LDL +HDL incubation and the increase
in the urinary albumin excretion, suggesting that either
LDL oxidisability or the properties of HDL in this animal
model of type II diabetes could be used as marker of
albuminuria and endothelial dysfunction. The low calorie
diet lowered total serum cholesterol, although no dietary
manipulations were made in fatty acid content that could
increase the LDL oxidative resistance. The relative content
in monounsaturated (MUFA) and polyunsaturated fatty
acids (PUFA) were the same in both the normal chow and
the 30%-less calorie diet. Nevertheless, we have clearly
shown an inhibition of oxidative LDL signal in the re-
strictive dietary group compared with the others. This
would be in agreement with the results of Hargrove et al.
[35] who showed differences in LDL oxidative susceptibil-
ity between different diets (although the objective of the
study was to evaluate the effects of diets high in MUFA
from different food sources on LDL oxidative susceptibil-
ity). They compared these effects with those of a Step II
blood cholesterol-lowering diet (25% total fat, 7% satu-
rated) as well as a higher fat average American diet (35%
total fat, 15% saturated). As regard to the two last diets,
they showed that the average American diet tended to
cause the shortest to LDL-oxidation lag time compared
with the Step II diet.
Telmisartan may mediate cholesterol efflux by activat-
ing PPAR. In this regard, Matsumura et al. [36] demon-
strated that telmisartan increased the expression of
CD36, ABCA1 and ABCG1, all PPAR-responsive genes,
and the activation of LXR, a transcription factor that
also regulates ABCA1 and ABCG1 gene transcription in
macrophages. This finding corroborated previous reports
that telmisartan activated PPARγ target genes including
CD36 in monocytes [37] and that telmisartan increased
cholesterol efflux via PPARγ-dependent ABCA1 and
ABCG1 expression in macrophages [38].
Conclusions
In conclusion, this is the first study in which LDL oxida-
tive susceptibility and response to HDL incubation,
serum APOA1 as well as mRNA hepatic expression and
urinary albumin excretion are analysed in an obesity
related type II diabetes rat model subjected to either adietary intervention or a pharmacologic modulation of
PPAR gamma with telmisartan. Our results suggest
important beneficial effects of both interventions in
terms of LDL oxidative susceptibility and progression of
albuminuria in obesity related type II diabetes.
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